Tuesday, July 17, 2018, 11:00 A.M. CST -- Proving damages in patent pharmaceutical cases can be challenging, as the Georgia Pacific elements are not clearly adapted for pharma markets. Learn from two experienced practitioners how to successfully prove reasonable royalties in pharma cases after an at-risk launch. Join Jake M. Holdreith and Mark Robbins for a lively discussion of patent damages.
Jake M. Holdreith is a trial lawyer who leads the Hatch-Waxman practice at Robins Kaplan LLP. Mark Robbins is a pharmaceutical attorney and consultant at Kodiak Strategic Consultants who frequently testifies as an expert witness on pharmaceutical antitrust and patent litigation, including reasonable royalty rate determinations. He has over 30 years of experience in leadership positions in legal, regulatory, and scientific roles at leading pharmaceutical companies and extensive experience in pharma licensing.
SPEAKER
Partner,
Industry Leader, Health and Life Sciences;
Member of the Executive Board
